IT0005574659 20240902 6.25 (I09839) News

QIAGEN announces 2028 strategy for solid profitable growth

Venlo, the Netherlands, and New York, June 17, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) will announce today...

QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs

Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today...

QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth

Venlo, the Netherlands, June 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2023...

QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance

Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

Venlo, the Netherlands, June 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to...

QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

Venlo, the Netherlands, June 05, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA...

QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today...

Form SD - Specialized disclosure report

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB...

Form S-8 - Securities to be offered to employees in employee benefit plans

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN;...

QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine

Venlo, the Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA...

QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support

Venlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an updated version...

QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results

Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today...